DeutschNewstral
Article
Mmarketwatch.com on 2018-10-22 13:37
Mirati Therapeutics stock drops 30% premarket after cancer trial results
Related news
- MMirati Therapeutics' stock soars on heavy volume after positive cancer treatment trial resultsmarketwatch.com
What’s Next For Mirati Therapeutics Stock After A 20% Rise In A Month?Forbes- MNektar Therapeutics stock drops after resultsmarketwatch.com
- IBristol-Myers is spending $5.8 billion to buy Mirati Therapeuticsinvezz.com
- MViking Therapeutics stock jumps 4.8% premarket on news of positive trial resultsmarketwatch.com
- MSangamo stock drops 13% premarket on results of phase 1/2 gene editing trialmarketwatch.com
- MSangamo Therapeutics stock drops 23% on results of cutting-edge gene-editing trialmarketwatch.com
- MOnconova Therapeutics stock drops 12% after pricing stock offeringmarketwatch.com
- MG1 Therapeutics' stock drops on heavy volume after stock offeringmarketwatch.com
- MFlexion Therapeutics stock soars 24% premarket as FDA approves label change for OA keen pain therapymarketwatch.com
- MSpark Therapeutics stock plummets 28% premarket on hemophilia trial's patient safety concernsmarketwatch.com
- MViking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatmentmarketwatch.com
- MUPDATE: Cara Therapeutics shares surge 13.7% premarket on positive trial resultsmarketwatch.com
- MReebonz's stock tumbles to pace premarket decliners after disappointing resultsmarketwatch.com
- IViking Therapeutics stock doubles on weight-loss drug trial resultsinvezz.com
- BCrispr Therapeutics Stock Spikes on Positive Gene-Editing Resultsbarrons.com
- MMenlo Therapeutics' stock plunges over 50% after disappointing trial resultsmarketwatch.com
- MProteostasis Therapeutics' stock more than triples after positive trial resultsmarketwatch.com
- MZuora stock drops following results, outlookmarketwatch.com
- MPivotal Software's stock drops after quarterly resultsmarketwatch.com